Relapse Prevention Study Of Desvenlafaxine Succinate Sustained Release In Outpatients With Major Depressive Disorder

PHASE3CompletedINTERVENTIONAL
Enrollment

874

Participants

Timeline

Start Date

June 30, 2009

Primary Completion Date

March 31, 2011

Study Completion Date

March 31, 2011

Conditions
Major Depressive Disorder
Interventions
DRUG

Desvenlafaxine succinate sustained release 50 mg

50 mg tablet, once daily. 5 months open-label duration for all enrolled subjects; additional 6 months double-blind duration for randomized subjects assigned to this arm.

DRUG

Desvenlafaxine succinate sustained release 25 mg

25 mg tablet for taper, once daily for 1 week

DRUG

Placebo

Matching placebo tablet, once daily. 6 months double-blind duration for randomized subjects assigned to placebo.

Trial Locations (90)

3000

Pfizer Investigational Site, Kaunas

3630

Pfizer Investigational Site, Durban

4730

Pfizer Investigational Site, Strenči

Pfizer Investigational Site, Strenči

7530

Pfizer Investigational Site, Cape Town

7646

Pfizer Investigational Site, Paarl

10000

Pfizer Investigational Site, Zagreb

10024

Pfizer Investigational Site, New York

10128

Pfizer Investigational Site, New York

10204

Pfizer Investigational Site, Vilnius

12618

Pfizer Investigational Site, Tallinn

14000

Pfizer Investigational Site, Caen

14618

Pfizer Investigational Site, Rochester

20100

Pfizer Investigational Site, Turku

20852

Pfizer Investigational Site, Rockville

30080

Pfizer Investigational Site, Smyrna

30328

Pfizer Investigational Site, Atlanta

32256

Pfizer Investigational Site, Jacksonville

33100

Pfizer Investigational Site, Tampere

33143

Pfizer Investigational Site, South Miami

33702

Pfizer Investigational Site, St. Petersburg

33716

Pfizer Investigational Site, St. Petersburg

35000

Pfizer Investigational Site, Rennes

39100

Pfizer Investigational Site, Dole

44700

Pfizer Investigational Site, Orvault

45408

Pfizer Investigational Site, Dayton

51000

Pfizer Investigational Site, Rijeka

51003

Pfizer Investigational Site, Tartu

59500

Pfizer Investigational Site, Douai

Pfizer Investigational Site, Douai

60100

Pfizer Investigational Site, Seinäjoki

60169

Pfizer Investigational Site, Hoffman Estates

65608

Pfizer Investigational Site, Võru

Pfizer Investigational Site, Vöru

70110

Pfizer Investigational Site, Kuopio

78247

Pfizer Investigational Site, San Antonio

80045

Pfizer Investigational Site, Aurora

80100

Pfizer Investigational Site, Joensuu

90210

Pfizer Investigational Site, Beverly Hills

90720

Pfizer Investigational Site, Los Alamitos

91101

Pfizer Investigational Site, Trenčín

91316

Pfizer Investigational Site, Encino

91786

Pfizer Investigational Site, Upland

92868

Pfizer Investigational Site, Orange

97210

Pfizer Investigational Site, Portland

98104

Pfizer Investigational Site, Seattle

200317

Pfizer Investigational Site, Craiova

400012

Pfizer Investigational Site, Cluj-Napoca

500123

Pfizer Investigational Site, Brasov

7530193

Pfizer Investigational Site, Santiago

7630000

Pfizer Investigational Site, Santiago

8330838

Pfizer Investigational Site, Santiago

T6L 6W6

Pfizer Investigational Site, Edmonton

T1B 4E7

Pfizer Investigational Site, Medicine Hat

V1Y 1Z9

Pfizer Investigational Site, Kelowna

V6Z 2L4

Pfizer Investigational Site, Vancouver

E2A 4X7

Pfizer Investigational Site, Bathurst

L7R 4E2

Pfizer Investigational Site, Burlington

K1G 4G3

Pfizer Investigational Site, Ottawa

M9W 4L6

Pfizer Investigational Site, Toronto

J9A 1K7

Pfizer Investigational Site, Gatineau

H9R 4S3

Pfizer Investigational Site, Pointe-Claire

J1H 4J6

Pfizer Investigational Site, Sherbrooke

Unknown

Pfizer Investigational Site, Medellín

Pfizer Investigational Site, Barranquilla

Pfizer Investigational Site, Bogota

Pfizer Investigational Site, Bucamaranga

Pfizer Investigational Site, Tallinn

Pfizer Investigational Site, Sigulda

Pfizer Investigational Site, Vilius

02600

Pfizer Investigational Site, Espoo

00100

Pfizer Investigational Site, Helsinki

LV-3400

Pfizer Investigational Site, Liepāja

LV-2150

Pfizer Investigational Site, Sigulda

LT-50185

Pfizer Investigational Site, Kaunas

LT-09112

Pfizer Investigational Site, Vilnius

LT-10204

Pfizer Investigational Site, Vilnius

60-185

Pfizer Investigational Site, Skorzewo

71-460

Pfizer Investigational Site, Szczecin

87-100

Pfizer Investigational Site, Torun

95-080

Pfizer Investigational Site, Tuszyn

50-227

Pfizer Investigational Site, Wroclaw

09-300

Pfizer Investigational Site, Żuromin

010825

Pfizer Investigational Site, Bucharest

041914

Pfizer Investigational Site, Bucharest

972 01

Pfizer Investigational Site, Bojnice

820 07

Pfizer Investigational Site, Bratislava

031 23

Pfizer Investigational Site, Liptovský Mikuláš

071 01

Pfizer Investigational Site, Michalovce

979 12

Pfizer Investigational Site, Rimavská Sobota

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT00887224 - Relapse Prevention Study Of Desvenlafaxine Succinate Sustained Release In Outpatients With Major Depressive Disorder | Biotech Hunter | Biotech Hunter